Jasper Bos, PhD, a former Merck executive, joined Forbion as General Partner for the firm’s Growth Fund.
Before joining Forbion’s Naarden-based headquarters, Jasper was Senior Vice President and Managing Director at M Ventures, the venture arm of pharmaceutical giant Merck, which he joined in 2009. At M Ventures, he led a team of twenty-one investment professionals and with a fund size of €400 million invested in over 50 portfolio companies spanning biotech, life sciences tools, and tech companies with investment activities ranging from seed-stage to cross-over and IPO.
His track record includes the successful exits of Prexton Therapeutics, Epitherapeutics, Galecto, ObsEva, Translate Bio, and F-Star. He has experience in several operational roles in portfolio companies and played a key role in the creation of multiple successful spin-out companies out of Merck.
Jasper holds a PhD in Pharmacy from the University of Groningen, the Netherlands.
Throughout my career I have been fortunate enough to support brilliant founders in their search for novel treatments for patients in need. At Forbion, I have the privilege of continuing this journey every day — partnering with visionary entrepreneurs and leveraging our deep scientific expertise and entrepreneurial spirit to help bring transformative therapies to market. Together, we will turn groundbreaking science into real-world solutions for patients worldwide.
Portfolio
Companies worked on by Jasper Bos
